Surviving Covid-19 with Heparin?
作者信息
Ten Cate Hugo
机构信息
From the Thrombosis Expertise Center, Department of Internal Medicine, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands, and the Center for Thrombosis and Hemostasis, Gutenberg University Medical Center, Mainz, Germany.
出版信息
N Engl J Med. 2021 Aug 26;385(9):845-846. doi: 10.1056/NEJMe2111151. Epub 2021 Aug 4.
Abstract
摘要
相似文献
1
Surviving Covid-19 with Heparin?使用肝素治疗新冠病毒肺炎能否存活？
N Engl J Med. 2021 Aug 26;385(9):845-846. doi: 10.1056/NEJMe2111151. Epub 2021 Aug 4.
2
'Heparin rebound' means the opposite in cardiac surgery (bleeding) and in cardiology (thrombosis).“肝素反跳”在心脏外科手术（出血）和心脏病学（血栓形成）中含义相反。
Blood Coagul Fibrinolysis. 2010 Mar;21(2):198-9. doi: 10.1097/MBC.0b013e3283370126.
3
[LMWH and UFH in direct comparison. Consent: CERTIFY].[低分子量肝素与普通肝素的直接比较。同意：证明]
MMW Fortschr Med. 2007 May 17;149(20):53.
4
European practice guidelines: thromboembolism prophylaxis and regional anesthesia.欧洲实践指南：血栓栓塞预防与区域麻醉
Reg Anesth Pain Med. 1998 Nov-Dec;23(6 Suppl 2):178-82. doi: 10.1016/s1098-7339(98)90144-4.
5
Secondary prophylaxis with low molecular weight heparin: the dose?低分子量肝素的二级预防：剂量是多少？
Thromb Haemost. 2001 Oct;86(4):1129.
6
Antiplatelet therapy or low-dose heparin and neuraxial anaesthesia.抗血小板治疗或小剂量肝素与椎管内麻醉。
Acta Anaesthesiol Scand Suppl. 1997;111:219-21.
7
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety.肝素与低分子量肝素：作用机制、药代动力学、给药考量、监测、疗效及安全性
Chest. 1998 Nov;114(5 Suppl):489S-510S. doi: 10.1378/chest.114.5_supplement.489s.
8
[Low-molecular-weight heparin in deep venous thrombosis. Dosage for all weight classes].[低分子量肝素用于深静脉血栓形成。所有体重级别的剂量]
MMW Fortschr Med. 2003 Jun 12;145(24):56.
9
[Anticoagulation of the extracorporeal circuit in chronic hemodialysis].[慢性血液透析中体外循环的抗凝]
Nephrologie. 1998;19(4):223-5.
10
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
引用本文的文献
1
Assessing differential application of thromboprophylaxis regimes related to risk of pulmonary embolism and mortality in COVID-19 patients through instrumental variable analysis.通过工具变量分析评估与 COVID-19 患者肺栓塞风险和死亡率相关的血栓预防方案的差异应用。
Sci Rep. 2025 Mar 25;15(1):10321. doi: 10.1038/s41598-024-77858-w.
2
Quantitative Prediction of Protein-Polyelectrolyte Binding Thermodynamics: Adsorption of Heparin-Analog Polysulfates to the SARS-CoV-2 Spike Protein RBD.蛋白质-聚电解质结合热力学的定量预测：肝素类似物多硫酸盐对严重急性呼吸综合征冠状病毒2刺突蛋白受体结合域的吸附
JACS Au. 2025 Jan 6;5(1):204-216. doi: 10.1021/jacsau.4c00886. eCollection 2025 Jan 27.
3
The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid.肝素和类肝素在急性和重度炎症紊乱中的预防和治疗作用。
Biomolecules. 2024 Aug 28;14(9):1078. doi: 10.3390/biom14091078.
4
Intermediate dose enoxaparin in hospitalized patients with moderate-severe COVID-19: a pilot phase II single-arm study, INHIXACOVID19.住院的中重度 COVID-19 患者中中等剂量依诺肝素：一项 INHIXACOVID19 的 II 期单臂先导研究。
BMC Infect Dis. 2023 Oct 24;23(1):718. doi: 10.1186/s12879-023-08297-7.
5
The Prevalence of Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎患者胃肠道出血的发生率：系统评价和荟萃分析。
Medicina (Kaunas). 2023 Aug 21;59(8):1500. doi: 10.3390/medicina59081500.
6
Anticoagulant therapy in COVID-19: A narrative review.新型冠状病毒肺炎的抗凝治疗：叙述性综述。
Clin Transl Sci. 2023 Sep;16(9):1510-1525. doi: 10.1111/cts.13569. Epub 2023 Jun 30.
7
Clinical Disease Characteristics and Treatment Trajectories Associated with Mortality among COVID-19 Patients in Punjab, Pakistan.巴基斯坦旁遮普省新冠肺炎患者的临床疾病特征及与死亡率相关的治疗轨迹
Healthcare (Basel). 2023 Apr 21;11(8):1192. doi: 10.3390/healthcare11081192.
8
Population Pharmacokinetics and Probability of Target Attainment Analysis of Nadroparin in Different Stages of COVID-19.COVID-19 不同阶段那屈肝素的群体药代动力学和目标达成概率分析。
Clin Pharmacokinet. 2023 Jun;62(6):835-847. doi: 10.1007/s40262-023-01244-4. Epub 2023 Apr 25.
9
The diverse role of heparan sulfate and other GAGs in SARS-CoV-2 infections and therapeutics.硫酸乙酰肝素和其他糖胺聚糖在 SARS-CoV-2 感染和治疗中的多样作用。
Carbohydr Polym. 2023 Jan 1;299:120167. doi: 10.1016/j.carbpol.2022.120167. Epub 2022 Sep 28.
10
Anticoagulant Use During Extracorporeal Membrane Oxygenation Using Heparin and Direct Thrombin Inhibitors in COVID-19 and ARDS Patients.COVID-19 和 ARDS 患者体外膜肺氧合中肝素和直接凝血酶抑制剂的抗凝使用。
J Extra Corpor Technol. 2022 Sep;54(3):223-234. doi: 10.1182/ject-223-234.
本文引用的文献
1
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
2
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
3
Platform Trials - Beware the Noncomparable Control Group.平台试验——谨防不可比的对照组。
N Engl J Med. 2021 Apr 22;384(16):1572-1573. doi: 10.1056/NEJMc2102446.
4
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.近期 COVID-19 患者抗血栓治疗的随机临床试验：美国心脏病学会最新综述。
J Am Coll Cardiol. 2021 Apr 20;77(15):1903-1921. doi: 10.1016/j.jacc.2021.02.035. Epub 2021 Mar 16.
5
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.COVID-19 重症监护患者中中剂量与标准剂量预防抗凝对血栓事件、体外膜肺氧合治疗或死亡率的影响：INSPIRATION 随机临床试验。
JAMA. 2021 Apr 27;325(16):1620-1630. doi: 10.1001/jama.2021.4152.
6
Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis.2019冠状病毒病患者发生静脉血栓栓塞的风险：一项系统评价和荟萃分析
Res Pract Thromb Haemost. 2020 Oct 13;4(7):1178-1191. doi: 10.1002/rth2.12439. eCollection 2020 Oct.
7
The unique characteristics of COVID-19 coagulopathy.COVID-19 凝血功能障碍的独特特征。
Crit Care. 2020 Jun 18;24(1):360. doi: 10.1186/s13054-020-03077-0.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素：一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
Low-molecular-weight heparin: is small beautiful?低分子量肝素：小即是美？
N Engl J Med. 1986 Oct 9;315(15):957-9. doi: 10.1056/NEJM198610093151509.
Zotero 插件